SubsidieMeestersintegrated nano-photonic OMICs bio-SENSor for lung cancer
OMICSENS aims to develop a novel nano-photonic omics bio-sensor for real-time detection of TKI resistance in NSCLC, enhancing prognosis and paving the way for personalized cancer treatment.
Projectdetails
Introduction
OMICSENS aims to develop a radically new omics measurement platform that would be initially applied to improve non-small cell lung cancer (NSCLC) prognosis by ensuring a timely and accurate detection of Tyrosine Kinase Inhibitor (TKI) resistance associated with Epidermal Growth Factor Receptor (EGFR) mutations. Subsequently, OMICSENS will be used to improve the prognosis of patients suffering from other types of cancers.
Technology Development
OMICSENS targets the creation of the first nano-photonic integrated omics bio-sensor to tackle TKI resistance and improve NSCLC treatment outcomes and patient prognosis.
Technology Components
Thanks to OMICSENS, we will build a six-layer technology comprised of:
- An on-chip embedded infra-red source array
- An artificial intelligence optimized nano-structured surface for photonic signal enhancement
- A functionalized surface of high absorbance to specific analytes
- A microfluidics system to deliver the sample
- A metamaterial-based photo detector array with optimized quantum efficiency
- An AI algorithm enabling analyte quantification
Future Applications
Our miniaturized omics bio-sensor will enable real-time and concurrent measurements of omics, compatible with organ-on-chip (OOC) in the future. OOC is one of the most promising bioengineering developments, paving the way to more efficient drug testing and personalized medicine through digital twinning of a biological system. However, OOC is lacking a real-time, integrated bio-sensing technology.
Disruptive Innovation
OMICSENS proposes a disruptive bio-sensor to bridge this gap. This new device will be useful for telehealth, capable of improving medical diagnostics while fostering a patient-centered approach.
Collaborative Effort
To achieve our novel and ambitious objective, we have brought together an interdisciplinary consortium of top-level academics (LMU, UNITN, IBEC, KTH) and SMEs (MW, QAI, 4K-MEMS), including expertise in:
- Oncology
- Bio-engineering
- Micro-fluidics
- Biochemistry
- MEMS
- Nano-photonics
- Computational physics
- Artificial intelligence
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.372.318 |
| Totale projectbegroting | € 2.372.318 |
Tijdlijn
| Startdatum | 1-1-2024 |
| Einddatum | 31-12-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- UNIVERSITA DEGLI STUDI DI TRENTOpenvoerder
- LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
- MULTIWAVE TECHNOLOGIES
- FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
- KUNGLIGA TEKNISKA HOEGSKOLAN
- 4K-MEMS SA
- QUAISR LIMITED
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A multiplexed biomimetic imaging platform for assessing single cell plasticity (Plastomics) and scoring of tumour malignancyThe PLAST_CELL project aims to develop a microfluidics-based imaging platform to quantify cancer cell plasticity, enhancing diagnosis and treatment of metastasis and therapy resistance. | EIC Pathfinder | € 2.982.792 | 2022 | Details |
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation. | EIC Pathfinder | € 2.996.550 | 2022 | Details |
Smart Electronic Olfaction for Body Odor DiagnosticsSMELLODI aims to digitize and synthesize olfactory information for remote disease diagnostics and assist individuals with olfactory disorders using advanced sensor technology and machine learning. | EIC Pathfinder | € 3.263.781 | 2022 | Details |
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images. | EIC Pathfinder | € 2.744.300 | 2022 | Details |
A multiplexed biomimetic imaging platform for assessing single cell plasticity (Plastomics) and scoring of tumour malignancy
The PLAST_CELL project aims to develop a microfluidics-based imaging platform to quantify cancer cell plasticity, enhancing diagnosis and treatment of metastasis and therapy resistance.
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"
The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation.
Smart Electronic Olfaction for Body Odor Diagnostics
SMELLODI aims to digitize and synthesize olfactory information for remote disease diagnostics and assist individuals with olfactory disorders using advanced sensor technology and machine learning.
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.
The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Nano-assisted digitalizing of cancer phenotyping for immunotherapyThe ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes. | ERC COG | € 1.993.875 | 2023 | Details |
On-demand COMmunication between fluorescent organic nanoparticles through Energy TransferThe COMET project aims to develop innovative optical biosensors using communicating fluorescent organic nanoparticles for real-time detection of opioids in complex biological media. | ERC STG | € 1.500.000 | 2023 | Details |
RESTORING IMMUNITY CONTROL OF GI CANCERSTIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization. | EIC Transition | € 2.007.750 | 2025 | Details |
DETACT - Detection of Enzymes and muTAtions for Cancer TreatmentCytura Therapeutics en ENPICOM ontwikkelen een innovatieve diagnostische assay voor vroege kankerdetectie door het meten van enzymactiviteit en mutatiepatronen in bloedcellen. | MIT R&D Samenwerking | € 215.845 | 2019 | Details |
Nano-assisted digitalizing of cancer phenotyping for immunotherapy
The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.
On-demand COMmunication between fluorescent organic nanoparticles through Energy Transfer
The COMET project aims to develop innovative optical biosensors using communicating fluorescent organic nanoparticles for real-time detection of opioids in complex biological media.
RESTORING IMMUNITY CONTROL OF GI CANCERS
TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.
DETACT - Detection of Enzymes and muTAtions for Cancer Treatment
Cytura Therapeutics en ENPICOM ontwikkelen een innovatieve diagnostische assay voor vroege kankerdetectie door het meten van enzymactiviteit en mutatiepatronen in bloedcellen.